About: Major molecular response achieved with dasatinib in a CML patient with F317L BCR-ABL kinase domain mutation

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Major molecular response achieved with dasatinib in a CML patient with F317L BCR-ABL kinase domain mutation Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
Description	Mutations of BCR-ABL tyrosine kinase domain represent the most frequently identified and best-studied mechanism of chronic myeloid leukemia (CML) resistance to the treatment with tyrosine kinase inhibitors (TKIs). In previously reported patients with F317L BCR-ABL kinasedomain mutation response to dasatinib treatment was invariably poor. We describe a CML patient in chronic phase with F317L mutation identified shortly after the initiation of dasatinib therapy,following previous imatinib failure. Despite a continual persistence of the F317L mutation, thepatient achieved a complete cytogenetic and a major molecular response after 4 and 6 months of dasatinib treatment, respectively, and maintained the response for more than 20 months of followup.Possible explanations for this long-term favourable response may include immune-mediatedeffects associated with dasatinib therapy, elimination of proliferative advantage of F317L-mutant cells through inhibition of Src family of kinases (SFK) or the presence of F3 Mutations of BCR-ABL tyrosine kinase domain represent the most frequently identified and best-studied mechanism of chronic myeloid leukemia (CML) resistance to the treatment with tyrosine kinase inhibitors (TKIs). In previously reported patients with F317L BCR-ABL kinasedomain mutation response to dasatinib treatment was invariably poor. We describe a CML patient in chronic phase with F317L mutation identified shortly after the initiation of dasatinib therapy,following previous imatinib failure. Despite a continual persistence of the F317L mutation, thepatient achieved a complete cytogenetic and a major molecular response after 4 and 6 months of dasatinib treatment, respectively, and maintained the response for more than 20 months of followup.Possible explanations for this long-term favourable response may include immune-mediatedeffects associated with dasatinib therapy, elimination of proliferative advantage of F317L-mutant cells through inhibition of Src family of kinases (SFK) or the presence of F3 (en)
Title	Major molecular response achieved with dasatinib in a CML patient with F317L BCR-ABL kinase domain mutation Major molecular response achieved with dasatinib in a CML patient with F317L BCR-ABL kinase domain mutation (en)
skos:prefLabel	Major molecular response achieved with dasatinib in a CML patient with F317L BCR-ABL kinase domain mutation Major molecular response achieved with dasatinib in a CML patient with F317L BCR-ABL kinase domain mutation (en)
skos:notation	RIV/61989592:15110/09:00009742!RIV10-MSM-15110___
http://linked.open...avai/riv/aktivita	P Z
http://linked.open...avai/riv/aktivity	P(NS9949), Z(MSM6198959205), Z(MSM6198959223)
http://linked.open...iv/cisloPeriodika	4
http://linked.open...vai/riv/dodaniDat	2010
http://linked.open...aciTvurceVysledku	PLACHÝ, Radek Faber, Edgar INDRÁK, Karel Rožmanová, Šárka Jarošová, Marie Divoká, Martina MOJZÍKOVÁ, Renáta
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Univerzita Palackého v Olomouci / Lékařská fakulta
http://linked.open...dnocenehoVysledku	324437
http://linked.open...ai/riv/idVysledku	RIV/61989592:15110/09:00009742
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	chronic myeloid leukemia; F317L BCR-ABL mutation; dasatinib; tyrosine kinase inhibitors (en)
http://linked.open.../riv/klicoveSlovo	tyrosine kinase inhibitors chronic myeloid leukemia dasatinib F317L BCR-ABL mutation
http://linked.open...odStatuVydavatele	GB - Spojené království Velké Británie a Severního Irska
http://linked.open...ontrolniKodProRIV	[9F7C47E59E16]
http://linked.open...i/riv/nazevZdroje	Leukemia Research
http://linked.open...in/vavai/riv/obor	FD
http://linked.open...ichTvurcuVysledku	7 (xsd:int)
http://linked.open...cetTvurcuVysledku	8 (xsd:int)
http://linked.open...vavai/riv/projekt	The role of in vitro sensitivity to tyrosine kinase inhibitors estimation in management of patients with chronic myeloid leukemia
http://linked.open...UplatneniVysledku	2009
http://linked.open...v/svazekPeriodika	34
http://linked.open...iv/tvurceVysledku	Faber, Edgar Indrák, Karel Jarošová, Marie Divoká, Martina Rožmanová, Šárka Mojzíková, Renáta Plachý, Radek Šťastný, Marek
http://linked.open...n/vavai/riv/zamer	Studies of genes and molecular mechanisms involved in regulation of hematopoiesis, their clinical impact and targeted treatment Nové možnosti diagnostiky a imunomodulace u infekčních onemocnění a imunopatologických stavů
issn	0145-2126
number of pages	3 (xsd:int)
http://localhost/t...ganizacniJednotka	15110

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 47 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software